Compare Heron Therapeutics Inc (HRTX) vs Vanguard Value Index Fund ETF (VTV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Vanguard Value Index Fund ETF — how do they compare? Heron Therapeutics Inc trades at $0.36 (market cap $68.01M), while Vanguard Value Index Fund ETF trades at $219.8 (market cap $262.40B). The key difference: Vanguard Value Index Fund ETF is far larger — about 3858.3× Heron Therapeutics Inc's market cap, and Vanguard Value Index Fund ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Vanguard Value Index Fund ETF for 142 Days on average.
| HRTX | VTV | |
|---|---|---|
Market Cap | $68.01M | $262.40B |
Volume | 1,891,941 | 3,293,281 |
Sector | Health | — |
52-Week High | $1.49 | $227.51 |
52-Week Low | $0.27 | $182.86 |
Typical Hold Time | 35 Days | 142 Days |
Enterprise Value | $174.75M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
Vanguard Value ETF (VTV) trades at $218.21, down 0.35% on the day amid a bearish technical signal. The ETF shows neutral momentum oscillators but bearish moving averages, with key support at $217 and resistance at $219. Recent institutional buying by QRG Capital Management and Blue Edge Capital reflects confidence in value strategies, while news highlights VTV's 2.3% dividend yield and outperformance versus growth ETFs in 2026.
VTV offers exposure to large-cap value stocks with a low 0.03% expense ratio, appealing for income and stability. Risks include prolonged underperformance versus growth sectors and market rotation sensitivity. Analyst sentiment is mixed, balancing dividend appeal against broader market trends. The ETF remains a core holding for value-focused portfolios amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Vanguard Value Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →
